Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$27.82 ▲ +0.60
(+2.20%)
MKT CAP: $1.07B • VOL: 405.3K
52W L $11 52W H $28
CBLL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $89.1M | $65.4M | $45.2M |
| YoY Revenue Growth % | +36.1% | +44.7% | — |
| Gross Profit | $78.3M | $56.8M | — |
| Gross Margin % | 87.9% | 86.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$58.4M | -$39.7M | -$30.0M |
| Operating Margin % | -65.6% | -60.7% | -66.4% |
| Net Income (GAAP) | -$53.4M | -$40.5M | -$29.5M |
| EBITDA (Normalized) | -$57.8M | -$38.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$40.8M | -$35.0M | -$29.2M |
| Capital Expenditures (CapEx) | $767.0K | $1.3M | — |
| Free Cash Flow (FCF) | -$41.6M | -$36.4M | -$29.2M |
| FCF Margin % | -46.7% | -55.6% | -64.5% |
| Return on Invested Capital (ROIC %) | -40.2% | -45.0% | — |
| Cash & Short-Term Equivalents | $40.5M | $194.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $155.3M | $191.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CBLL.